Product Description
Product Name: Bryxta 100 mg Injection
Active Ingredient: Bevacizumab
Strength: 100 mg/4 mL
Form: Solution for Intravenous Infusion
Category: Anticancer / Monoclonal Antibody / Anti-Angiogenic Agent
Indication: Brain Tumors, Breast Cancer, Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Solid Tumors
Bryxta 100 mg Injection is an anticancer medication containing Bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). By blocking VEGF, Bryxta helps inhibit the growth of new blood vessels (angiogenesis) that supply oxygen and nutrients to tumors, thereby slowing or stopping cancer progression.
